Market's view on N4 Pharma Plc
Published on April 2024
- There are speculations about the potential benefits of a new collaboration aimed to enhance market exposure and possibly aid funding.
- The company is nearing finalisation of a collaboration with a US-based global leader in R&D, which could lead to a co-marketing agreement.
- Concerns are raised regarding the company’s financial health, citing less than GBP1m in cash and no revenue generation.
- Updates on the oral delivery research for Nuvec®, including successful in vivo tests showing promising results for multiple nucleotide payloads.
- There is criticism of the company’s previous projects, like the abandoned sildenafil formulation, indicating a pattern of underperformance.
- Doubts are expressed about the credibility of the company’s publications and the need for more substantiated updates from the management.